| LncRNA |
Compound |
Cancer |
P-value |
Effect |
| ENSG00000227533.1 |
ABT-263 (navitoclax) |
Lung squamous cell carcinoma |
0.037545096 |
Resistant |
| ENSG00000227533.1 |
ABT-263 (navitoclax) |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
0.045195249 |
Sensitive |
